title: Kinetics of E-selectin expression in surgical flaps.
abstract: During the ischemia/reperfusion phenomenon, adhesion molecules seem to play a critical role in the recruitment of neutrophils to sites of eventual tissue injury. E-selectin is an endothelium-derived molecule that mediates adhesion of neutrophils to activated endothelial cells. In vitro expression of E-selectin, after exposure to stimuli such as endotoxin, interleukin 1, or tumor necrosis factor alpha is maximal at 4 to 6 h, followed by a decline toward basal levels at 24 to 48 h. Characterizing the temporal expression of E-selectin in an in vivo model of skin flap ischemia-reperfusion would help to determine the optimal approach to eventual pharmacologic blockade. This intervention may prove therapeutically beneficial in attenuating flap injury. This study, using the standard porcine buttock skin flap model, was designed to evaluate immunohistochemically the expression of E-selectin in flaps subjected to (1) arterial ischemia (8 h)-reperfusion (18 h), (2) venous ischemia (8 h)-reperfusion (18 h), and (3) distal ischemia (26 h). Four flaps were examined per group, with 8 biopsies being collected sequentially over the 26-h study period from each flap. Blinded, semi-quantitative histologic scoring revealed the following results: (1) E-selectin is absent in normal porcine skin; (2) with arterial ischemia/reperfusion, E-selectin expression in flaps was maximal at 1 h of reperfusion, declining thereafter; (3) with venous ischemia/reperfusion, E-selectin expression peaked during the first hour of ischemia, with subsequent decline; and (4) within a flap designed to sustain distal ischemia, E-selectin expression is relatively more intense in regions of the flap distant from the vascular pedicle, and maximal at 6 h after flap elevation. Our conclusion, therefore, is that the kinetics of E-selectin expression within the tissues of porcine skin flaps differs depending on the type of ischemic insult sustained. Interpretation of these findings, correlating possible pathophysiologic differences in the different models of ischemia, is offered.
authors.affiliation: Microsurgical Laboratories, Royal Victoria Hospital and McGill University, Montreal, Quebec, Canada.
authors.forename: C
authors.initials: C
authors.lastname: Wang
authors.forename: C L
authors.initials: CL
authors.lastname: Kerrigan
authors.forename: M A
authors.initials: MA
authors.lastname: Stotland
mesh_terms: D000818:Animals; D002448:Cell Adhesion; D004195:Disease Models, Animal; D019040:E-Selectin / Q000032:analysis* / Q000235:genetics; D004730:Endothelium, Vascular / Q000473:pathology; D004731:Endotoxins / Q000009:adverse effects; D005069:Evaluation Studies as Topic; D005260:Female; D005500:Follow-Up Studies; D005786:Gene Expression Regulation; D007150:Immunohistochemistry; D007375:Interleukin-1 / Q000502:physiology; D007511:Ischemia / Q000378:metabolism / Q000473:pathology; D007700:Kinetics; D018482:Muscle, Skeletal / Q000098:blood supply / Q000473:pathology / Q000637:transplantation; D018375:Neutrophil Activation; D009504:Neutrophils / Q000473:pathology; D011897:Random Allocation; D015424:Reperfusion; D016037:Single-Blind Method; D016038:Skin Transplantation / Q000473:pathology; D013524:Surgical Flaps / Q000098:blood supply / Q000473:pathology; D013552:Swine; D014409:Tumor Necrosis Factor-alpha / Q000502:physiology
chemical_list: D019040:E-Selectin; D004731:Endotoxins; D007375:Interleukin-1; D014409:Tumor Necrosis Factor-alpha